With help from Lu­l­ule­mon founder’s ven­ture phil­an­thropy, Vi­ta adds sec­ond mus­cu­lar dy­s­tro­phy in­di­ca­tion to line­up

Ear­li­er this year, Lu­l­ule­mon’s founder Chip Wil­son went pub­lic with his rare dis­ease di­ag­no­sis of fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy type 2, or FSHD type 2, in which the mus­cles de­gen­er­ate over time. Wil­son al­so com­mit­ted $100 mil­lion to find a cure for FSHD through a new ven­ture, Solve FSHD.

Now, up to $10 mil­lion of that com­mit­ment is go­ing to Vi­ta Ther­a­peu­tics, a Bal­ti­more-based cell ther­a­py biotech, and Vi­ta will be adding a dis­cov­ery-phase FSHD cell ther­a­py to its pipeline. Solve FSHD’s ex­ec­u­tive di­rec­tor Eva Chin will al­so be join­ing Vi­ta’s board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER